List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
Researchers have identified two molecules that can improve the response of pancreatic cancer to a common chemotherapy drug and also predict the prognosis of pancreatic cancer patients...
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer...
The move will help funded research progress toward the development of new therapeutics
Phase 2 trial to explore targeted therapies for children with solid tumours that harbour specific genetic mutations which have progressed during or after standard therapy...
Scientists discover, a potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer...
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer...
BenevolentAI announced today it has hired Dr Nathan Brown, as its new Head of Cheminformatics following the promotion of Mark Davies...
Researchers have developed a new tools to increase immune response against cancer and infections...
Cancer Research UK has launched the second phase of its global Grand Challenge by announcing eight new questions – identified as some of the biggest barriers to making progress against cancer – and inviting the world’s top scientists to come together with new proposals to tackle them.
Included in this Stem Cells In-Depth Focus: Translating discoveries into therapies; The key to successful manufacturing of patient-specific cell therapies; Interview with Alessandro Prigione and James Adjaye...
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer's disease...
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced updates to its expanding oncology discovery business, including significant additions to its online Tumor Model Compendium...
Scientists will develop and test promising new molecules for targeting RAS, one of the most common driving mutations in aggressive, hard to treat cancers including pancreatic and lung cancer.
Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL) launched a multi-year strategic partnership to advance new programs spanning the disease areas of immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.
